StockNews.AI
NVNO
StockNews.AI
172 days

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

1. enVVeno Medical's cash burn aligns with projections, indicating stable finances. 2. FDA decision for VenoValve expected in late 2025, pivotal trial prep underway.

FDA Approval
-9.92%Current Return
VS
+1.56%S&P 500
$3.5302/28 08:07 AM EDTEvent Start
$3.1803/03 08:19 AM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Stable cash burn indicates effective financial management while awaiting regulatory decisions. Prior FDA approvals often positively influenced stock performance historically.

How important is it?

The progress on regulatory submissions and financial stability are crucial for market confidence and can drive stock performance positively.

Why Long Term?

Regulatory milestones are critical and can lead to significant future growth for NVNO by late 2025.

Related Companies

CRISNXGNABCL
Cash Burn of $5.2 million in Q4 remains in line with projected $4-5 million quarterly range Cash and investments on hand are sufficient to fund operations beyond the anticipated regulatory approval of VenoValve and the initiation of the enVVe pivotal trial PMA application for the VenoValve submitted, with FDA decision expected in the second half of 2025 On track for enVVe IDE application submission by mid-2025, pending GLP study results IRVINE, CA / ACCESS Newswire / February 28, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today provided a corporate update and reported financial results for the fourth quarter and year-end of 2024. "Throughout 2024, we executed on our primary objectives - the successful submission of our PMA application for the VenoValve®, and the advancement of enVVe towards its U.S. pivotal trial, both critical milestones for enVVeno Medical," commented Robert Berman, CEO of enVVeno Medical.

Related News